Figure 6.

Astrocytic IL-10 receptor has a pivotal role in mediating the therapeutic effect of nasal anti-CD3. ( A ) Schematic map of the astrocyte-specific shRNA lentiviral vector. ( B–D ) Intracerebroventricular injection of astrocyte-specific sh IL10ra lentivirus ameliorates disease severity. NOD mice were injected intracerebroventricularly (i.c.v.) with 10 ⁷ IU of shControl, or sh IL10ra lentivirus (LV, black arrow), at Day 35 after EAE induction (progressive phase). n = 10 mice per group. Two weeks after i.c.v. injection the experiment was terminated and ( B ) immunostaining analysis of spinal cord slices from mock- or lentivirus-infected mice identify GFP ⁺ expression only in GFAP ⁺ astrocytes. ( C ) Il10ra expression levels were determined by quantitative PCR in astrocytes isolated from naïve or EAE NOD mice; expression normalized to gapdh and presented relative to that of cells from naïve mice. Representative data of two independent experiments, Statistical analysis by one-way ANOVA, followed by Tukey post hoc analysis. ( D ) EAE clinical scores. Representative data of two independent experiments. Statistical analysis by two-way ANOVA. ** P < 0.01, *** P < 0.001.